DE60027768D1 - Behandlung von metastatischer krankheit - Google Patents

Behandlung von metastatischer krankheit

Info

Publication number
DE60027768D1
DE60027768D1 DE60027768T DE60027768T DE60027768D1 DE 60027768 D1 DE60027768 D1 DE 60027768D1 DE 60027768 T DE60027768 T DE 60027768T DE 60027768 T DE60027768 T DE 60027768T DE 60027768 D1 DE60027768 D1 DE 60027768D1
Authority
DE
Germany
Prior art keywords
treatment
metastatic disease
compounds
metastatic
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE60027768T
Other languages
English (en)
Other versions
DE60027768T2 (de
Inventor
Scott Kinch
Katherine E Kilpatrick
D Zantek
W Hein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
University of North Carolina at Chapel Hill
Purdue Research Foundation
University of North Carolina System
Original Assignee
Glaxo Group Ltd
University of North Carolina at Chapel Hill
Purdue Research Foundation
University of North Carolina System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22529456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60027768(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd, University of North Carolina at Chapel Hill, Purdue Research Foundation, University of North Carolina System filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DE60027768D1 publication Critical patent/DE60027768D1/de
Publication of DE60027768T2 publication Critical patent/DE60027768T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60027768T 1999-08-17 2000-08-17 Behandlung von metastatischer krankheit Revoked DE60027768T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14925899P 1999-08-17 1999-08-17
US149258P 1999-08-17
PCT/US2000/022670 WO2001012172A1 (en) 1999-08-17 2000-08-17 Treatment of metastatic disease

Publications (2)

Publication Number Publication Date
DE60027768D1 true DE60027768D1 (de) 2006-06-08
DE60027768T2 DE60027768T2 (de) 2007-04-05

Family

ID=22529456

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60027768T Revoked DE60027768T2 (de) 1999-08-17 2000-08-17 Behandlung von metastatischer krankheit

Country Status (10)

Country Link
EP (2) EP2289940A3 (de)
JP (2) JP2003516930A (de)
AT (1) ATE324877T1 (de)
AU (1) AU6784400A (de)
CA (1) CA2380888A1 (de)
DE (1) DE60027768T2 (de)
DK (1) DK1242060T3 (de)
ES (1) ES2261230T3 (de)
PT (1) PT1242060E (de)
WO (1) WO2001012172A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US7192698B1 (en) 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
SK288201B6 (sk) 2000-03-31 2014-06-03 Purdue Research Foundation Farmaceutický prostriedok
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
EP1298221A1 (de) * 2001-09-28 2003-04-02 PrimaGen Holding B.V. Mittel und Methoden für die Abschätzung einer Behandlung
EP1225233A3 (de) * 2001-01-23 2003-01-08 Amsterdam Support Diagnostics B.V. Mittel und Methoden für die Abschätzung einer Behandlung
NZ537458A (en) * 2001-01-23 2007-02-23 Primagen Holding B Means and methods for treatment evaluation
JP2005523878A (ja) * 2001-09-28 2005-08-11 パーデュー・リサーチ・ファウンデーション リガンド・免疫原物質複合体を用いた処置方法
WO2003070883A2 (en) * 2002-02-15 2003-08-28 Millennium Pharmaceuticals, Inc. Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
WO2004014292A2 (en) * 2002-05-10 2004-02-19 Purdue Research Foundation EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
CA2485373A1 (en) * 2002-05-10 2003-11-20 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
WO2003099313A1 (en) 2002-05-23 2003-12-04 Purdue Research Foundation Low molecular weight protein tyrosine phosphatase (lmw-ptp) as a diagnostic and therapeutic target
AU2004210463B2 (en) * 2003-02-07 2009-07-16 Ludwig Institute For Cancer Research Limited Eph/ephrin mediated modulation of cell adhesion and tumour cell metastasis
AU2003900541A0 (en) * 2003-02-07 2003-02-20 Ludwig Institute For Cancer Research Modulation of cell adhesion and tumour cell metastasis
WO2004091375A2 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Epha2 and non-neoplastic hyperproliferative cell disorders
JP2006523240A (ja) * 2003-04-11 2006-10-12 メディミューン，インコーポレーテッド ＥｐｈＡ２、低増殖性細胞障害ならびに上皮および内皮の再構成
WO2004101764A2 (en) 2003-05-13 2004-11-25 Chiron Corporation Methods of modulating metastasis and skeletal related events resulting from metastases
WO2005016381A2 (en) * 2003-07-21 2005-02-24 Medimmune, Inc. Combination therapy for the treatment and prevention of cancer using epha2, pcdgf, and haah
CN1905899B (zh) * 2003-11-20 2011-09-28 医学免疫公司 EphA2激动性单克隆抗体及其使用方法
WO2005113782A1 (en) 2004-05-18 2005-12-01 Alphavax, Inc. Tc-83-derived alphavirus vectors, particles and methods
US7659374B2 (en) 2004-08-16 2010-02-09 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
CN104059150B (zh) 2005-02-04 2018-10-02 宏观基因有限公司 结合epha2的抗体及其使用方法
US8168164B2 (en) 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
USRE47123E1 (en) 2006-07-18 2018-11-13 Sanofi EPHA2 receptor antagonist antibodies
AU2007342333B2 (en) 2006-09-12 2013-02-28 Alphavax, Inc. Alphavirus replicon particles encoding IL- 12 as immunological adjuvants
CA2663295C (en) 2006-09-12 2020-03-10 Alphavax, Inc. Alphavirus replicon particles matched to protein antigens as immunological adjuvants
NZ576563A (en) 2006-11-03 2012-09-28 Alphavax Inc Alphavirus and alphavirus replicon particle formulations and methods
TWI443109B (zh) * 2007-08-30 2014-07-01 Daiichi Sankyo Co Ltd 抗ｅｐｈａ２抗體
AR078470A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis Anticuerpos que se unen especificamente al receptor epha2
JP5875054B2 (ja) * 2013-02-13 2016-03-02 国立大学法人 東京大学 がんの検査方法及び検査用キット
JP6729917B2 (ja) * 2016-08-19 2020-07-29 国立大学法人 東京大学 ＥｐｈＡ２ Ｎ末端フラグメント抗体
WO2020028749A1 (en) 2018-08-03 2020-02-06 Uab Research Foundation Methods and compositions for alphavirus vaccine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514554A (en) 1991-08-22 1996-05-07 Becton Dickinson And Company Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy
US5811098A (en) 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
CA2103323A1 (en) * 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
US5587459A (en) 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
DE69925024T2 (de) * 1998-11-20 2006-03-02 Genentech, Inc., South San Francisco Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten

Also Published As

Publication number Publication date
EP1242060A4 (de) 2003-09-24
CA2380888A1 (en) 2001-02-22
DE60027768T2 (de) 2007-04-05
EP1242060B1 (de) 2006-05-03
ES2261230T3 (es) 2006-11-16
EP2289940A3 (de) 2011-09-21
PT1242060E (pt) 2006-08-31
DK1242060T3 (da) 2006-08-21
EP2289940A2 (de) 2011-03-02
AU6784400A (en) 2001-03-13
WO2001012172B1 (en) 2001-08-16
WO2001012172A1 (en) 2001-02-22
JP2003516930A (ja) 2003-05-20
JP2007306938A (ja) 2007-11-29
EP1242060A1 (de) 2002-09-25
ATE324877T1 (de) 2006-06-15

Similar Documents

Publication Publication Date Title
ATE324877T1 (de) Behandlung von metastatischer krankheit
GB9903762D0 (en) Organic compounds
TR200003514T2 (tr) Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri
TR200200928T2 (tr) 2-pirazolin-5-on terkipleri
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
BR9814361A (pt) Inibição de quinase raf usando uréiasheterocìclicas substituìdas por arila eheteroarila
TR199800012T1 (xx) Piroloprimidinler ve preparasyon i�in tatbikler.
ATE292971T1 (de) (s,s)-reboxetin zur behandlung von peripheren neuropathien
WO2005030121A3 (en) Compounds, compositions and methods
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
ATE305300T1 (de) Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
BR0209149A (pt) Ftalazinonas
EA200600424A1 (ru) Применение полипептидов семейства купредоксинов при лечении рака
EA200800011A1 (ru) Тиенопиримидиновые и тиенопиридиновые модуляторы киназы
TR200401316T4 (tr) Proliferatif hastalıkları tedavi etmek için yöntemler ve bileşikler
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
TR200200260T2 (tr) N-desmetilzopiklonlarının üretim ve kullanım yöntemleri
TR200201250T2 (tr) Hidroksieikosatetraenoat tuzları, bileşimleri ve bunların göz kuruması bozukluklarının iyileştirilmesinde kullanım yöntemleri.
DE60033918D1 (de) Polysubstituted 6-phenylphenanthridines mit pde-iv hemmender wirkung
DE60115466D1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
DE60019894D1 (de) Phenantrhridin-n-oxides mit pde-iv hemmender wirkung
ES2185323T3 (es) Utilizacion de eritropoietina en el tratamiento del mieloma multiple.
ATE287886T1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation